Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

The Potential Return on Public Investment in Detecting Adverse Drug Effects.

Huybrechts KF, Desai RJ, Park M, Gagne JJ, Najafzadeh M, Avorn J.

Med Care. 2017 Jun;55(6):545-551. doi: 10.1097/MLR.0000000000000717.

PMID:
28505041
2.

Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort.

Daniels B, Lord SJ, Kiely BE, Houssami N, Haywood P, Lu CY, Ward RL, Pearson SA; HER2 therapy observational study (HER2-OBS) investigators.

BMJ Open. 2017 Jan 24;7(1):e014439. doi: 10.1136/bmjopen-2016-014439.

4.

Con: Phosphate binders in chronic kidney disease.

Kestenbaum B.

Nephrol Dial Transplant. 2016 Feb;31(2):189-94. doi: 10.1093/ndt/gfv406. Epub 2015 Dec 17. Review.

5.

The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers.

Mellish L, Karanges EA, Litchfield MJ, Schaffer AL, Blanch B, Daniels BJ, Segrave A, Pearson SA.

BMC Res Notes. 2015 Nov 2;8:634. doi: 10.1186/s13104-015-1616-8.

6.

An introduction to the fundamentals of cohort and case-control studies.

Gamble JM.

Can J Hosp Pharm. 2014 Sep;67(5):366-72. No abstract available.

7.

The use and impact of cancer medicines in routine clinical care: methods and observations in a cohort of elderly Australians.

Pearson SA, Schaffer A.

BMJ Open. 2014 May 2;4(5):e004099. doi: 10.1136/bmjopen-2013-004099.

8.
9.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

10.

The value of observational cohort studies for cancer drugs.

Spigel DR.

Biotechnol Healthc. 2010 Summer;7(2):18-24.

11.

Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure.

Delate T, Bowles EJ, Pardee R, Wellman RD, Habel LA, Yood MU, Nekhlyudov L, Goddard KA, Davis RL, McCarty CA, Onitilo AA, Feigelson HS, Freml J, Wagner E.

Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):673-80. doi: 10.1158/1055-9965.EPI-11-1075. Epub 2012 Feb 15.

12.

Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century.

Khoury MJ, Clauser SB, Freedman AN, Gillanders EM, Glasgow RE, Klein WM, Schully SD.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2105-14. doi: 10.1158/1055-9965.EPI-11-0481. Epub 2011 Jul 27. Review.

13.

Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres.

Madarnas Y, Dent SF, Husain SF, Robinson A, Alkhayyat S, Hopman WM, Verreault JL, Vandenberg T.

Curr Oncol. 2011 Jun;18(3):119-25.

14.

Uptake of novel medical therapies in the general population.

Booth CM, Rapoport B.

Curr Oncol. 2011 Jun;18(3):105-8. No abstract available.

15.

Use of the self-controlled case series method in drug safety assessment.

Grosso A, Douglas I, MacAllister R, Petersen I, Smeeth L, Hingorani AD.

Expert Opin Drug Saf. 2011 May;10(3):337-40. doi: 10.1517/14740338.2011.562187. Epub 2011 Mar 15. No abstract available.

16.

Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort.

de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, White NH, Danis RP, Davis MD, Hainsworth D, Hubbard LD, Nathan DM.

Arch Intern Med. 2011 Mar 14;171(5):412-20. doi: 10.1001/archinternmed.2011.16.

17.

Costs and benefits of free medications after myocardial infarction.

Dhalla IA, Smith MA, Choudhry NK, Denburg AE.

Healthc Policy. 2009 Nov;5(2):68-86.

18.

Registration of observational studies: is it time?

Williams RJ, Tse T, Harlan WR, Zarin DA.

CMAJ. 2010 Oct 19;182(15):1638-42. doi: 10.1503/cmaj.092252. Epub 2010 Jul 19. No abstract available.

19.

Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records.

Brownstein JS, Murphy SN, Goldfine AB, Grant RW, Sordo M, Gainer V, Colecchi JA, Dubey A, Nathan DM, Glaser JP, Kohane IS.

Diabetes Care. 2010 Mar;33(3):526-31. doi: 10.2337/dc09-1506. Epub 2009 Dec 15.

20.

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.

Abelson A, Ringe JD, Gold DT, Lange JL, Thomas T.

Osteoporos Int. 2010 Jun;21(6):1021-9. doi: 10.1007/s00198-009-1046-3. Epub 2009 Sep 1.

Supplemental Content

Support Center